Key result
The Mehran risk score model was evaluated for predicting contrast-induced nephropathy after cardiac resynchronization therapy in heart failure patients, but no results were reported in the abstract.
Why the study?
Does the Mehran risk score predict contrast-induced nephropathy in heart failure patients undergoing cardiac resynchronization therapy?
Cohort
No
Does the Mehran risk score predict contrast-induced nephropathy in heart failure patients undergoing cardiac resynchronization therapy?
This study evaluates the utility of the Mehran risk score for predicting contrast-induced nephropathy in heart failure patients undergoing CRT implantation.
Evaluation yields no predictive data; leaves open Mehran score utility for CIN after CRT in HF.
Methods: This single-center, retrospective study included HF patients who underwent CRT implantation. The patients had New York Heart Association class II-IV disease, wide QRS in electrocardiogram (>130 ms), and diminished left ventricular ejection fraction (<35%). Patients with active bleeding, acute renal failure before the CRT procedure, liver cirrhosis, autoimmune disease, chronic or acute inflammatory diseases, end-stage malignancy, and receiving dialysis were excluded. Mehran CIN risk score was calculated using the patient records.
No takes yet. Share an insight, caveat, or question.
Erdöl et al. (2022) conducted a cohort in Heart failure. Mehran risk score was evaluated on Contrast-induced nephropathy. The Mehran risk score model was evaluated for predicting contrast-induced nephropathy after cardiac resynchronization therapy in heart failure patients, but no results were reported in the abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: